---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-074355"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:47:43.226271+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cadrenal reports Q2 net loss $3.7M, cash $5.6M; plans tecarfarin trial in ESKD dialysis patients

## Summary
- Net loss of $3.7M for Q2 2025 versus $2.4M in Q2 2024; G&A increased to $2.7M from $1.2M.
- Cash and equivalents $5.6M at June 30, 2025, down from $10.0M at December 31, 2024.
- Plans to initiate clinical trial of tecarfarin in ESKD patients transitioning to dialysis; site activation expected later in 2025.
- Completed technical transfer and cGMP manufacturing of tecarfarin drug substance at a U.S. CDMO site.
- Added to Russell 3000E and Russell Microcap indexes effective June 30, 2025.

## SEC filing metadata
- accession: 0001213900-25-074355
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025074355/0001213900-25-074355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025074355/ea0252643-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-074355
- JSON: https://secwatch.observer/filing/0001213900-25-074355.json
- Plain text: https://secwatch.observer/filing/0001213900-25-074355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.